

The Health Service (Benefit) (Limited List) (Pharmaceutical Benefit) (Amendment No. 7) Regulations, 2021

<i>Made</i>	30 th November, 2021
<i>Coming into operation</i>	1 st December, 2021
<i>Laid before the States</i>	, 2021

THE COMMITTEE FOR HEALTH & SOCIAL CARE, in exercise of the powers conferred on it by sections 10 and 35 of the Health Service (Benefit) (Guernsey) Law, 1990^a and section 1 of the Health Service (Benefit) (Limited Lists) Ordinance, 2004^b, and all other powers enabling it in that behalf, hereby makes the following Regulations:-

Amendment to the 2004 Regulations.

1. In the Schedule to the Health Service (Benefit) (Limited List) (Pharmaceutical Benefit) Regulations, 2004^c ("the 2004 Regulations") –

^a Ordres en Conseil Vol. XXXII, p. 192; amended by Order in Council No. IX of 2003; No. II of 2011; No. IV of 2018; Recueil d'Ordonnances Tome XXVI, pp. 177 and 483; Ordinance Nos. XXII and XXVII of 2002; Nos. XXI and XXXIII of 2003; No. XLII of 2006; No. XLIII of 2007; No. XXII of 2015; Nos. IX and XLIV of 2016; and No. XVI of 2020.

^b Ordinance No. XIII of 2004; amended by Ordinance No. XXXIV of 2013 and No. XXV of 2017.

^c G.S.I. No. 9 of 2004; amended by G.S.I. No. 42 of 2004; Nos 18, 25 and 38 of 2005; Nos 12, 18, 26, 36 and 46 of 2006; Nos 3, 5, 6, 16, 17 and 32 of 2007; Nos 11, 23, 29, 31, 47, 50 and 76 of 2008; Nos 16, 35, 43, 47 and 56 of 2009; Nos 5, 32, 48, 88, 91 and 99 of 2010; Nos 5, 13, 19, 37, 38 and 52 of 2011; Nos 5, 25, 33 and 52 of 2012; Nos 5, 27, 35, 42, 68, 78 and 87 of 2013; Nos 8, 11, 16, 25, 57, 69 and 99 of 2014; Nos 9, 33 and 106 of 2015; Nos 10, 17, 25, 31 and 49 of 2016; Nos 48, 69, 78, 88 and 117 of 2017; Nos 6, 9, 16, 28, 35, 40 and 43 of 2018; Nos 1, 68, 77, 82, 91, 106 and 114 of 2019; Nos. 3, 55, 93 and 144 of 2020 and Nos 16, 35, 60, 65, 101 and 105 of 2021.


- (a) insert the entries set out in Schedule 1 to these Regulations in the appropriate places and under the appropriate headings, and
- (b) delete the entries set out in Schedule 2.

Citation, commencement and extent.

2. (1) These Regulations may be cited as the Health Service (Benefit) (Limited List) (Pharmaceutical Benefit) (Amendment No. 7) Regulations, 2021, and shall come into force on the 1st day of December, 2021.

(2) These Regulations shall have effect in the Islands of Guernsey, Alderney, Herm and Jethou.

Dated this 30th day of November, 2021.



A. H. BROUARD

President of the States Committee for Health & Social Care

For and on behalf of the Committee

SCHEDULE 1

Regulation 1(a)

ENTRIES TO BE INSERTED IN THE SCHEDULE TO THE 2004 REGULATIONS

British National Formulary (BNF) Section	Heading	Pharmaceutical Benefit
2.12	Lipid-regulating Drugs	Bempedoic Acid, film-coated tablets, 180 mg. Bempedoic Acid/Ezetimibe, film-coated tablets, 180 mg/10 mg. (In accordance with NICE TA number 694 or any revision thereof only).
3.1	Respiratory disease/Airways disease/obstructive	Benralizumab, solution for injection in pre-filled syringe and pre-filled pen, 30mg. (In accordance with NICE TA number 565 or any revision thereof only). Specialist use only.
3.3.4	Antidepressants/Selective Serotonin and Noradrenaline Re-uptake inhibitors	Venlafaxine Oral Suspension, 37.5mg/5ml.
5.6.5	Infection/Viral Infection/HIV Infection	Biktarvy, (Tenofovir alafenamide fumarate/Bictegravir/Emtricitabine) tablets (25mg/50mg/200mg). PEH pharmacy dispensing only and for MDT recommendation only.
8/8.1	Immune System/Immune System Disorders and Transplantation	Azathioprine, oral suspension, 100ml, 50mg/5ml. Drug Tariff Special Order, for tube fed patients only.
8/8.3	Malignant Disease/Cytotoxic Responsive Malignancy	Hydroxycarbamide, oral solution SF, 150ml, 100 mg/ml. Specialist use only.
8/8.4	Malignant Disease/Hormone Responsive Malignancy	Darolutamide, film-coated tablets, 300mg. (In accordance with NICE TA number 660 or any revision thereof only). Specialist use only.
8/8.7	Malignant Disease/Targeted Therapy Responsive Malignancy	Lenvatinib, hard capsules 4mg, 10mg. (In accordance with NICE TA number 498 or any revision thereof only). Specialist use only.

British National Formulary (BNF) Section	Heading	Pharmaceutical Benefit
8/8.7	Malignant Disease/Targeted Therapy Responsive Malignancy	Lenvatinib, hard capsules 4mg, 10mg. (In accordance with NICE TA number 551 or any revision thereof only). Specialist use only.
9.1.5a	Nutrition and metabolic disorders/Fluid and electrolyte imbalances/Potassium imbalance/Hyperkalaemia	Sodium zirconium cyclosilicate, powder for oral suspension, 5g and 10g. (In accordance with NICE TA number 599 or any revision thereof only).
9/2.2	Nutrition and Metabolic Disorders/Metabolic Disorders/Amyloidosis/Neuroprotective drugs	Tafamidis, Soft capsules, 61mg. (In accordance with NICE TA number 696 or any revision thereof only).
12	Warts and Callouses Antiseptics and disinfectants/immune response modifiers	Imiquinod Cream 3.75% sachets

SCHEDULE 2

Regulation 1(b)

ENTRIES TO BE DELETED IN THE SCHEDULE TO
THE 2004 REGULATIONS

British National Formulary (BNF) Section	Heading	Pharmaceutical Benefit
8/8.3	Malignant Disease/Cytotoxic Responsive Malignancy	<p>Hydroxycarbamide, oral suspension, 300mg/5ml and 500mg/5ml.</p> <p>It will not be supplied to pharmacies without a letter from the prescriber confirming the reason(s) why the licensed solution is not appropriate.</p>

EXPLANATORY NOTE

(This note is not part of the Regulations)

These Regulations add drugs to the list of products that may be prescribed as pharmaceutical benefit. They also remove one existing drug from the list.

These Regulations come into force on the 1st December, 2021.